Patents by Inventor Martin J. Hicks

Martin J. Hicks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
    Patent number: 12122844
    Abstract: The invention provides methods to inhibit or treat brain cancers by locally inhibiting expression or activity of growth factors or growth factor receptors.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: October 22, 2024
    Assignees: Cornell University, Memorial Sloan-Kettering Cancer Center
    Inventors: Ronald G. Crystal, Stephen M. Kaminsky, Martin J. Hicks, Viviane Tabar
  • Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
    Patent number: 12024568
    Abstract: The invention provides methods to inhibit or treat brain cancers by locally inhibiting expression or activity of growth factors or growth factor receptors.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: July 2, 2024
    Assignees: Cornell University, Memorial Sloan-Kettering Cancer Center
    Inventors: Ronald G. Crystal, Stephen M. Kaminsky, Martin J. Hicks, Viviane Tabar
  • TREATMENT OF BRAIN CANCERS USING CENTRAL NERVOUS SYSTEM MEDIATED GENE TRANSFER OF MONOCLONAL ANTIBODIES
    Publication number: 20210171656
    Abstract: The invention provides methods to inhibit or treat brain cancers by locally inhibiting expression or activity of growth factors or growth factor receptors.
    Type: Application
    Filed: July 13, 2020
    Publication date: June 10, 2021
    Inventors: Ronald G. Crystal, Stephen M. Kaminsky, Martin J. Hicks, Viviane Tabar
  • AAV-directed persistent expression of an anti-nicotine antibody gene for smoking cessation
    Patent number: 10093947
    Abstract: The invention is directed to an adeno-associated virus (AAV) vector which comprises a nucleic acid sequence encoding an antibody or antigen binding fragment that binds to nicotine or a nicotine analog. The invention also is directed to a composition comprising the AAV vector and methods of using the AAV vector to induce an immune response against nicotine in a mammal.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: October 9, 2018
    Assignee: CORNELL UNIVERSITY
    Inventors: Ronald G. Crystal, Martin J. Hicks, Jonathan B. Rosenberg, Bishnu P. De, Stephen M. Kaminsky, Robin L. Davisson
  • Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
    Patent number: 10004811
    Abstract: The invention is directed to a conjugate which comprises an isolated adenovirus hexon protein coupled to nicotine or a nicotine analog, as well as a method of inducing an immune response against nicotine in a human by using the conjugate.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: June 26, 2018
    Assignee: CORNELL UNIVERSITY
    Inventors: Ronald G. Crystal, Jonathan B. Rosenberg, Bishnu P. De, Martin J. Hicks, Stephen M. Kaminsky
  • DEVELOPMENT OF A HIGHLY EFFICIENT SECOND GENERATION NICOTINE-CONJUGATE VACCINE TO TREAT NICOTINE ADDICTION
    Publication number: 20150297739
    Abstract: The invention is directed to a conjugate which comprises an isolated adenovirus hexon protein coupled to nicotine or a nicotine analog, as well as a method of inducing an immune response against nicotine in a human by using the conjugate.
    Type: Application
    Filed: March 14, 2013
    Publication date: October 22, 2015
    Inventors: Ronald G. Crystal, Jonathan B. Rosenberg, Bishnu P. De, Martin J. Hicks, Stephen M. Kaminsky
  • AAV-DIRECTED PERSISTENT EXPRESSION OF AN ANTI-NICOTINE ANTIBODY GENE FOR SMOKING CESSATION
    Publication number: 20150056251
    Abstract: The invention is directed to an adeno-associated virus (AAV) vector which comprises a nucleic acid sequence encoding an antibody that binds to nicotine or a nicotine analog, or an antigen-binding fragment thereof. The invention also is directed to a composition comprising the AAV vector and methods of using the AAV vector to induce an immune response against nicotine in a mammal.
    Type: Application
    Filed: February 25, 2013
    Publication date: February 26, 2015
    Inventors: Ronald G. Crystal, Martin J. Hicks, Jonathan B. Rosenberg, Bishnu P. De, Stephen M. Kaminsky, Robin L. Davisson